Skip to main content

Table 1 Patient and tumor characteristics

From: Risks and complications of transurethral resection of bladder tumors in patients receiving antiplatelet and/or anticoagulant therapy: a retrospective cohort study

 

AP/AC

  

Continuation (A)

n = 19, n (%)

Interruption (B)

n = 18, n (%)

Control (C)

n = 137, n (%)

p value

A vs B

A vs C

B vs C

Median age (range)

77

(57–89)

81

(58–90)

72

(38–90)

0.14

0.12

0.00322

Sex

 Male

17

(88%)

14

(78%)

97

(71%)

0.40

0.10

0.78

 Female

2

(12%)

4

(22%)

40

(29%)

Tumor size

  < 1 cm

10

(53%)

8

(44%)

71

(52%)

0.75

1.0

0.62

  ≥ 1 cm

9

(47%)

10

(56%)

66

(48%)

Tumor number

 Single

11

(58%)

12

(67%)

71

(52%)

0.74

0.81

0.32

 Multiple

8

(42%)

6

(33%)

66

(48%)

T classification at TURBT

 pT0–a

8

(42%)

7

(39%)

53

(39%)

0.43

0.71

0.35

 pT1

9

(47%)

10

(56%)

59

(43%)

 Min. pT2

2

(11%)

1

(5%)

25

(18%)

De novo

10

(53%)

10

(56%)

83

(61%)

>0.95

0.62

0.80

Recurrence

9

(47%)

8

(44%)

54

(39%)

  1. AP antiplatelet agents, AC anticoagulant agents, Min minimum